Soros Fund Management LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 29.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,100,000 shares of the company's stock after buying an additional 250,000 shares during the period. Soros Fund Management LLC owned about 1.74% of Evolus worth $12,144,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Evolus in the fourth quarter valued at about $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus during the fourth quarter worth $106,000. Quantbot Technologies LP acquired a new position in shares of Evolus in the fourth quarter worth $118,000. Finally, Tradition Wealth Management LLC lifted its position in shares of Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after acquiring an additional 2,000 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Evolus
In other news, insider David Moatazedi sold 6,251 shares of the stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock worth $794,369 in the last ninety days. Insiders own 6.10% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently commented on EOLS. Barclays lifted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. BTIG Research started coverage on shares of Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.75.
Check Out Our Latest Report on Evolus
Evolus Trading Up 2.4 %
EOLS stock traded up $0.28 on Friday, hitting $12.08. 957,476 shares of the company were exchanged, compared to its average volume of 666,727. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $768.13 million, a price-to-earnings ratio of -13.27 and a beta of 0.97. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The business's fifty day moving average is $11.98 and its two-hundred day moving average is $12.77.
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Stories
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
